News Results
There are 651,599 News Results
May 21, 2024
Nordson Corporation (Nasdaq: NDSN) today reported results for the fiscal second quarter ended April 30, 2024. Sales were $651 million, comparable to the prior year’s second quarter sales of $650...
May 21, 2024
-- Findings from the extended LIBERTY studies and associated post-hoc analysis support the long-term efficacy and safety of ZYMFENTRA(TM), the first and only FDA-approved subcutaneous infliximab([1],[2]) -- Data from a...
May 22, 2024
-- Tax-free separations create independent, focused Electronics and Water companies that are global leaders in their respective industries -- New DuPont will remain a premier diversified industrial company with industry-leading...
May 24, 2024
American Woodmark Corporation (NASDAQ: AMWD) (the "Company") today announced results for its fourth fiscal quarter ended April 30, 2024 and its fiscal year ended April 30, 2024. “Our teams delivered...
May 28, 2024
- Steady growth in APHEXDA® adoption in first full quarter post-approval
May 29, 2024
Seltorexant, an investigational first-in-class therapy, met all primary and secondary endpoints in pivotal Phase 3 study in patients with major depressive disorder (MDD) with insomnia symptoms, as presented at ASCP...
May 30, 2024
-- Q1 Net Revenue: $1.161 billion, declined by (12)% year-on-year -- Q1 Gross Margin: 45.5% GAAP gross margin; 62.4% non-GAAP gross margin -- Q1 Diluted income (loss) per share: $(0.25)...
Jun 4, 2024
Donaldson Company, Inc. (NYSE: DCI) (Donaldson or the Company), a global leader in technology-led filtration products and solutions, today reported third quarter fiscal 2024 generally accepted accounting principles (GAAP) net...
Jun 6, 2024
ChargePoint Holdings, Inc. (NYSE:CHPT) (“ChargePoint”), a leading provider of networked solutions for charging electric vehicles (EVs), today reported results for its first quarter of fiscal year 2025 ended April 30,...
Jun 10, 2024
DelveInsight's analysis estimates that the postherpetic neuralgia market is expected to show positive growth, mainly attributed to increased incidence and the anticipated launch of novel therapies during the forecasted period...
